True histiocytic lymphoma following therapy for lymphoblastic neoplasms

Robert A. Soslow, R. Eric Davis, Roger A. Warnke, Michael L. Cleary, Onsi W. Kamel

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

True histiocytic lymphomas (THLs) are rare tumors in which the malignant cells show morphologic and immunophenotypic evidence of histiocytic differentiation. We describe THLs that arose after therapy for one case of T- lineage lymphoblastic lymphoma (LyL) and two cases of acute lymphoblastic leukemia (ALL) (both CD10+, one pre-B phenotype). The lymphoblastic neoplasms were not unusual in any way, and responded well to standard therapy. The THLs arose 10 to 20 months after complete remission was achieved for the lymphoblastic neoplasms, at which time there was still no clinical or pathologic evidence of the lymphoblastic neoplasms. All three THLs exhibited clinical and morphologic features of malignancy. Neoplastic cells in the THLs had abundant eosinophilic vacuolated cytoplasm and pleomorphic nuclei, and expressed histiocytic antigens in the absence of lymphocyte-specific lineage markers. Because THLs are rare neoplasms, their occurrence after otherwise successful therapy for lymphoblastic neoplasms in these three cases may constitute a distinct clinicopathologic entity.

Original languageEnglish (US)
Pages (from-to)5207-5212
Number of pages6
JournalBlood
Volume87
Issue number12
DOIs
StatePublished - Jun 15 1996
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'True histiocytic lymphoma following therapy for lymphoblastic neoplasms'. Together they form a unique fingerprint.

Cite this